Ripe for Private Equity Interest

ZNO is ripe for Private Equity Interest in that it has no debt, nonperforming management and executive, a reasonable brand yet under-marketed, good margins, strong IP yet could be validated further.

Private Equity would gear this up to:
- put in place a strong executive with global BDM experience in B2B (ex big pharma, global FMCG);
- accelerate marketing to build on brand awareness;
- build stronger longer standing distribution agreements with recognised distributors or even take further territories in-house.
- conversion of revenue and orders to cashflow
- invest in further IP validation to expand and reinforce exisitng library of clinical test data.

There historically have been to many distribution agreements signed up with wannabee partners trying to build a business off ZNO's IP. They do not have any sustainable business models and are thhere for the quick short term returns and move on.

This company has a future but in the hands of better stewards.